Literature DB >> 7831341

Induction of antibodies to the human immunodeficiency virus type 1 by immunization of baboons with immunoglobulin molecules carrying the principal neutralizing determinant of the envelope protein.

H Zaghouani1, S A Anderson, K E Sperber, C Daian, R C Kennedy, L Mayer, C A Bona.   

Abstract

The hypervariable region 3 (V3) within the disulfide-bridged loop of the envelope protein of the human immunodeficiency virus type 1 (HIV-1) contains an amino acid sequence that was defined as a principal neutralizing determinant (PND). A 19-amino acid residue consensus sequence (designated V3C) predicted from the PND sequences of 245 isolates as well as a sequence from the PND of the WMJ2 HIV-1 isolate (designated V3M) were expressed on the variable region of murine-human immunoglobulin (Ig) chimeras that were designated Ig-V3C and Ig-V3M, respectively. The HIV-1 sequences on the Ig chimeras preserved their antigenicity and interacted with antibodies specific for peptides encompassing the V3C and V3M sequences. In baboons, Ig-V3C and Ig-V3M induced antibodies that bound V3C and V3M peptides as well as the glycoprotein gp120 envelope protein of HIV-1 MN isolate. In addition, the baboons' antisera were able to prevent infection of CD4 SupT1 susceptible T cells by HIV-1 MN. Finally, Ig-V3M chimeras were able to stimulate in vitro production of antibodies specific for the HIV-1 envelope-derived peptides by lymphocytes from HIV-1-infected human subjects.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7831341      PMCID: PMC42796          DOI: 10.1073/pnas.92.2.631

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  27 in total

1.  V kappa and J kappa gene segments of A/J Ars-A antibodies: somatic recombination generates the essential arginine at the junction of the variable and joining regions.

Authors:  I Sanz; J D Capra
Journal:  Proc Natl Acad Sci U S A       Date:  1987-02       Impact factor: 11.205

Review 2.  NIH conference. Development and evaluation of a vaccine for human immunodeficiency virus (HIV) infection.

Authors:  A S Fauci; R C Gallo; S Koenig; J Salk; R H Purcell
Journal:  Ann Intern Med       Date:  1989-03-01       Impact factor: 25.391

3.  Induction of anti-human immunodeficiency virus (HIV) neutralizing antibodies in rabbits immunized with recombinant HIV--hepatitis B surface antigen particles.

Authors:  M L Michel; M Mancini; E Sobczak; V Favier; D Guetard; E M Bahraoui; P Tiollais
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

4.  Expression of the HTLV-III envelope gene by a recombinant vaccinia virus.

Authors:  S Chakrabarti; M Robert-Guroff; F Wong-Staal; R C Gallo; B Moss
Journal:  Nature       Date:  1986 Apr 10-16       Impact factor: 49.962

5.  Prospect for prevention of human immunodeficiency virus infection: purified 120-kDa envelope glycoprotein induces neutralizing antibody.

Authors:  W G Robey; L O Arthur; T J Matthews; A Langlois; T D Copeland; N W Lerche; S Oroszlan; D P Bolognesi; R V Gilden; P J Fischinger
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

6.  Molecular characterization of the A/J J558 family of heavy chain variable region gene segments.

Authors:  G A Rathbun; F Otani; E C Milner; J D Capra; P W Tucker
Journal:  J Mol Biol       Date:  1988-08-05       Impact factor: 5.469

7.  Active immunity against the CD4 receptor by using an antibody antigenized with residues 41-55 of the first extracellular domain.

Authors:  P Lanza; R Billetta; S Antonenko; M Zanetti
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-15       Impact factor: 11.205

8.  Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120.

Authors:  J R Rusche; K Javaherian; C McDanal; J Petro; D L Lynn; R Grimaila; A Langlois; R C Gallo; L O Arthur; P J Fischinger
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

9.  Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120.

Authors:  P W Berman; J E Groopman; T Gregory; P R Clapham; R A Weiss; R Ferriani; L Riddle; C Shimasaki; C Lucas; L A Lasky
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

10.  Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies.

Authors:  J L Dangl; T G Wensel; S L Morrison; L Stryer; L A Herzenberg; V T Oi
Journal:  EMBO J       Date:  1988-07       Impact factor: 11.598

View more
  3 in total

1.  The principle of delivery of T cell epitopes to antigen-presenting cells applied to peptides from influenza virus, ovalbumin, and hen egg lysozyme: implications for peptide vaccination.

Authors:  I B Rasmussen; E Lunde; T E Michaelsen; B Bogen; I Sandlie
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-21       Impact factor: 11.205

2.  Epitope-specific tolerance induction with an engineered immunoglobulin.

Authors:  E T Zambidis; D W Scott
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

3.  Presentation of a T cell receptor antagonist peptide by immunoglobulins ablates activation of T cells by a synthetic peptide or proteins requiring endocytic processing.

Authors:  K L Legge; B Min; N T Potter; H Zaghouani
Journal:  J Exp Med       Date:  1997-03-17       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.